BACKGROUNDTo evaluate the efficacy and toxicity of domestic paclitaxel-based regimens in the treatment of advanced lung cancer.

METHODSDomestic paclitaxel 135-175 mg/m² on day 1 of a 21-day cycle or 45-70 mg/m² on days 1, 8, and 15 of a 21-day or 28-day cycle. The domestic paclitaxel was respectively combined with platinum or ifosfamide to treat patients with non-small cell lung cancer (2 cases in stage IIIB, 25 in stage stage IV) or small cell lung cancer (1 extensive case, 3 limited cases).

RESULTSThere were 29 cases to be evaluated, complete response wasn't observed, partial response rate was 31.0% (9/29). The response rate for initial and retreated patients was 38.5% (5/13) and 25.0% (4/16) (P=0.688) respectively. The response rate of non-small cell lung cancer was 24.0% (6/25) and small cell lung cancer's was 3/4. The common adverse effects were hematological toxicity (28/31, 90.3%) and nausea/vomiting (28/31, 90.3%).

CONCLUSIONSCombined chemotherapy including domestic paclitaxel has better curative effect for advanced lung cancer and some tolerable adverse effects.